From Wikipedia, the free encyclopedia
Medication
Omidenepag
Trade names Eybelis, Omlonti Other names UR-7276, DE-117, Omidenepag isopropyl (
JAN
JP )
Routes of administration Topical
eye drops
ATC code
Legal status
Propan-2-yl 2-[[6-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]pyridin-2-yl]amino]acetate
CAS Number
PubChem
CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Formula C 26 H 28 N 6 O 4 S
Molar mass 520.61 g·mol−1 3D model (
JSmol )
CC(C)OC(=O)CNC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=N1
InChI=1S/C23H22N6O4S/c30-23(31)15-25-22-6-1-4-19(27-22)17-28(34(32,33)21-5-2-11-24-14-21)16-18-7-9-20(10-8-18)29-13-3-12-26-29/h1-14H,15-17H2,(H,25,27)(H,30,31)
Key:YHGSTSNEOJUIRN-UHFFFAOYSA-N
InChI=1S/C26H28N6O4S/c1-20(2)36-26(33)17-28-25-8-3-6-22(30-25)19-31(37(34,35)24-7-4-13-27-16-24)18-21-9-11-23(12-10-21)32-15-5-14-29-32/h3-16,20H,17-19H2,1-2H3,(H,28,30)
Key:VIQCWEGEHRBLAC-UHFFFAOYSA-N
Omidenepag , sold under the brand name Eybelis among others, is a
medication used for the treatment of
glaucoma and
ocular hypertension .
[1]
[3]
Omidenepag was approved for medical use in Japan in 2018,
[3] and in the United States in September 2022.
[2]
[4]
Medical uses
Omidenepag is
indicated for the treatment of glaucoma and ocular hypertension.
[1]
[3]
Adverse effects
The most common adverse effects of omidenepag are
conjunctival hyperemia and
macular edema , including
cystoid macular edema .
[3]
Pharmacology
Omidenepag isopropyl is a
prodrug that is converted by
hydrolysis of its
isopropyl
ester to the
active metabolite omidenepag.
[5] Omidenepag is a selective
prostaglandin E2 receptor
agonist .
[6]
[7]
History
Omidenepag was developed by
Ube Industries and
Santen Pharmaceutical .
[3]
References
^
a
b
c
"Omlonti- omidenepag isopropyl solution/ drops" . DailyMed . 30 September 2022. Retrieved 16 October 2022 .
^
a
b
"Drug Approval Package: Omlonti" . U.S.
Food and Drug Administration (FDA). 20 October 2022. Retrieved 4 December 2022 .
^
a
b
c
d
e
f Duggan S (December 2018). "Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval". Drugs . 78 (18): 1925–1929.
doi :
10.1007/s40265-018-1016-1 .
PMID
30465134 .
S2CID
53721056 .
^
"Santen and UBE Received FDA Approval for Omlonti (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension" (Press release). Santen. 26 September 2022. Retrieved 1 October 2022 – via Business Wire.
^
"Omidenepag isopropyl" . DrugCentral . Division of Translational Informatics at University of New Mexico.
Archived from the original on 8 January 2022. Retrieved 8 January 2022 .
^ Kirihara T, Taniguchi T, Yamamura K, Iwamura R, Yoneda K, Odani-Kawabata N, et al. (January 2018).
"Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent" . Investigative Ophthalmology & Visual Science . 59 (1): 145–153.
doi :
10.1167/iovs.17-22745 .
PMID
29332128 .
^ Ida Y, Hikage F, Umetsu A, Ida H, Ohguro H (September 2020).
"Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells" . Scientific Reports . 10 (1): 16018.
Bibcode :
2020NatSR..1016018I .
doi :
10.1038/s41598-020-72538-x .
PMC
7524797 .
PMID
32994409 .
External links